298 related articles for article (PubMed ID: 27543314)
21. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
Aghi M; Rabkin S; Martuza RL
J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
[TBL] [Abstract][Full Text] [Related]
22. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
[TBL] [Abstract][Full Text] [Related]
23. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.
Fukushima T; Takeshima H; Kataoka H
Anticancer Res; 2009 Nov; 29(11):4845-54. PubMed ID: 20032445
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic strategies for inhibiting invasion in glioblastoma.
Drappatz J; Norden AD; Wen PY
Expert Rev Neurother; 2009 Apr; 9(4):519-34. PubMed ID: 19344303
[TBL] [Abstract][Full Text] [Related]
25. Recent developments in drug delivery strategies for targeting DNA damage response in glioblastoma.
Morás AM; Henn JG; Steffens Reinhardt L; Lenz G; Moura DJ
Life Sci; 2021 Dec; 287():120128. PubMed ID: 34774874
[TBL] [Abstract][Full Text] [Related]
26. Extrachromosomal DNA: Redefining the pathogenesis of glioblastoma.
Shiras A; Mondal A
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188551. PubMed ID: 33892052
[TBL] [Abstract][Full Text] [Related]
27. What next for newly diagnosed glioblastoma?
Domingo-Musibay E; Galanis E
Future Oncol; 2015; 11(24):3273-83. PubMed ID: 26558493
[TBL] [Abstract][Full Text] [Related]
28. Problems of Glioblastoma Multiforme Drug Resistance.
Stavrovskaya AA; Shushanov SS; Rybalkina EY
Biochemistry (Mosc); 2016 Feb; 81(2):91-100. PubMed ID: 27260389
[TBL] [Abstract][Full Text] [Related]
29. Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome.
Cesarini V; Martini M; Vitiani LR; Gravina GL; Di Agostino S; Graziani G; D'Alessandris QG; Pallini R; Larocca LM; Rossi P; Jannini EA; Dolci S
Oncotarget; 2017 Feb; 8(8):13223-13239. PubMed ID: 28099939
[TBL] [Abstract][Full Text] [Related]
30. Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches.
Miranda A; Blanco-Prieto M; Sousa J; Pais A; Vitorino C
Int J Pharm; 2017 Oct; 531(1):372-388. PubMed ID: 28755993
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Translesion DNA Synthesis as a Novel Therapeutic Strategy to Treat Brain Cancer.
Choi JS; Kim CS; Berdis A
Cancer Res; 2018 Feb; 78(4):1083-1096. PubMed ID: 29259011
[TBL] [Abstract][Full Text] [Related]
32. Predictive biomarkers investigated in glioblastoma.
Tabouret E; Chinot O; Sanson M; Loundou A; Hoang-Xuan K; Delattre JY; Idbaih A
Expert Rev Mol Diagn; 2014 Sep; 14(7):883-93. PubMed ID: 25096963
[TBL] [Abstract][Full Text] [Related]
33. [Epigenetic regulation in glioblastomas].
Quillien V
Ann Pathol; 2009 Nov; 29 Spec No 1():S34-6. PubMed ID: 19887247
[No Abstract] [Full Text] [Related]
34. Molecular advances of brain tumors in radiation oncology.
Noda SE; El-Jawahri A; Patel D; Lautenschlaeger T; Siedow M; Chakravarti A
Semin Radiat Oncol; 2009 Jul; 19(3):171-8. PubMed ID: 19464632
[TBL] [Abstract][Full Text] [Related]
35. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
[TBL] [Abstract][Full Text] [Related]
36. Activation of KATP channels increases anticancer drug delivery to brain tumors and survival.
Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats T
Eur J Pharmacol; 2009 Jan; 602(2-3):188-93. PubMed ID: 19027730
[TBL] [Abstract][Full Text] [Related]
37. New Directions in the Treatment of Glioblastoma.
Reitman ZJ; Winkler F; Elia AEH
Semin Neurol; 2018 Feb; 38(1):50-61. PubMed ID: 29548052
[TBL] [Abstract][Full Text] [Related]
38. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
39. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.
Murat A; Migliavacca E; Gorlia T; Lambiv WL; Shay T; Hamou MF; de Tribolet N; Regli L; Wick W; Kouwenhoven MC; Hainfellner JA; Heppner FL; Dietrich PY; Zimmer Y; Cairncross JG; Janzer RC; Domany E; Delorenzi M; Stupp R; Hegi ME
J Clin Oncol; 2008 Jun; 26(18):3015-24. PubMed ID: 18565887
[TBL] [Abstract][Full Text] [Related]
40. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
Sato A; Sunayama J; Matsuda K; Seino S; Suzuki K; Watanabe E; Tachibana K; Tomiyama A; Kayama T; Kitanaka C
Stem Cells; 2011 Dec; 29(12):1942-51. PubMed ID: 21957016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
